Kemal Atlay - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Kemal Atlay's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Kemal Atlay

Kemal Atlay

Verified

Clinical News Editor, Australian Doctor

Sydney

Final Covers

Pc Gaming And Space Science , Tech

Journalist Type

Seniority Positions

Medium Formats

Content

Total articles 910

  • First subcutaneous immunotherapy for lung and liver cancers added to PBS

    By Kemal Atlay Verified| Australian Doctor Verified Thousands of Australians with advanced lung and liver cancer can now access subsidised subcutaneous immunotherapy that cuts treatment time to seven minutes. On 1 August, Roche’s subcutaneous formulation of atezolizumab (Tecentriq SC) became the first such programmed death-ligand 1 immunotherapy on the PBS. × If this is your first visit to the new AusDoc website, reset your password here.

    By Kemal Atlay Verified · Australian Doctor

    Aug. 06, 2024

  • Medical Must-See: Lower back pain signals a rare, fatal cancer

    By Kemal Atlay Verified| Australian Doctor Verified This Indonesian man’s lower back pain foreshadowed a more sinister diagnosis, with his doctors finding a rare, aggressive form of bone cancer infiltrating his soft tissue. The 50-year-old originally presented in 2021 with a six-month history of lower-left back pain that had gradually limited his activity. × If this is your first visit to the new AusDoc website, reset your password here. Remember MeForgot Password? Having trouble logging in? Back to sign in

    By Kemal Atlay Verified · Australian Doctor

    Aug. 01, 2024

  • First subcutaneous immunotherapy for lung and liver cancers added to PBS

    By Kemal Atlay Verified| Australian Doctor Verified Thousands of Australians with advanced lung and liver cancer can now access subsidised subcutaneous immunotherapy that cuts treatment time to seven minutes. On 1 August, Roche’s subcutaneous formulation of atezolizumab (Tecentriq SC) became the first such programmed death-ligand 1 immunotherapy on the PBS. × If this is your first visit to the new AusDoc website, reset your password here.

    By Kemal Atlay Verified · Australian Doctor

    Aug. 06, 2024

As seen in

Company Info

Australian Doctor

Discover better with the AusDoc community platform for doctors. AusDoc is a news and community platform, allowing doctors to connect with colleagues across the medical profession as well as keeping them informed with the latest news, opinion, clinical updates and education. Given the ever-growing complexity of medicine, a community where doctors can discuss and debate the latest issues with each other should be of benefit to everyone. Our aim is to create a more collaborative future for healthcare in Australia.

'+61 2 9422 2796

Founded: 1984